You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
隴神戎發(300534.SZ):布瑞哌唑口溶膜獲得藥物臨牀試驗批準通知書
格隆匯 03-28 19:52

格隆匯3月28日丨隴神戎發(300534.SZ)公佈,控股子公司甘肅普安製藥股份有限公司於2025年3月27日收到國家藥品監督管理局覈準簽發的《藥物臨牀試驗批準通知書》,藥物名稱:布瑞哌唑口溶膜。布瑞哌唑口溶膜可用於精神分裂症的治療。本次獲得該藥物的臨牀試驗批準,標誌着普安製藥開發的布瑞哌唑口溶膜可以正式開展臨牀研究,是該產品研發進程中又一重要進展。根據我國藥品註冊相關的法律法規要求,藥物在獲得藥物臨牀試驗批準通知書後,尚需開展臨牀試驗並經國家藥品監督管理局審評、審批通過後方可生產上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account